Abstract
The aim of this cross-sectional study was to analyze bone mineral density (BMD) and prevalence of osteopenia and osteoporosis in 30 men with prolactinoma, and compare them to 22 control subjects. BMD of lumbar spine and femur was evaluated by dual-energy X-ray absorptiometry. PRL, testosterone, estradiol, sexual hormone-binding globulin and free androgen and estrogen indexes (FAI and FEI, respectively) were measured in all the subjects. In patients with prolactinoma, mean values of PRL and testosterone were calculated for the 12-month period that preceded the study. The mean T-score of the four sites analyzed by bone densitometry was lower in men with prolactinoma than in controls (p-values: lumbar spine=0.015, femoral neck >0.0001, trochanter=0.037, total femur=0.036), and 55.6% of the former presented osteopenia or osteoporosis at one or more sites (p = 0.035). The lumbar spine was the most seriously affected site, where 29.6% had osteopenia and 14.8% had osteoporosis. By the time of BMD determination, significant associations were found between BMD and PRL, testosterone, FAI, estradiol, FEI, and duration of hypogonadism. Considering the period of 12 months that preceded BMD evaluation, trochanter BMD was associated with mean PRL levels, while there was an association between lumbar spine BMD and mean testosterone levels. However, the multiple regression analysis showed that estradiol was the main determinant of BMD. In conclusion, men with prolactinoma have high prevalence of osteopenia and osteoporosis. Bone loss in such patients is associated with hyperprolactinemia and hypogonadism, and mainly influenced by estrogen.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Vartej P, Poiana C, Vartej I. Effects of hyperprolactinemia on osteoporotic fracture risk in premenopausal women. Gynecol Endocrinol 2001, 15: 43–7.
Klibanski A, Greenspan S. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 1986, 315: 542–6.
Biller B, Baum H, Rosenthal D, Saxe V, Charpie P, Klibanski A. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992, 75: 692–7.
Greenspan S, Neer R, Ridgway E, Klibanski A. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med 1986, 104: 777–82.
Greenspan SL, Oppenheim D S, Klibanski A. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 1989, 110: 526–31.
Di Somma C, Colao A, Di Sarno A, et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998, 83: 807–13.
Colao A, Di Somma C, Loche S, et al. Prolactinomas in adolescents: Persistance of bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf) 2000, 52: 319–27.
Jackson J, Kleerekoper M, Parfitt M. Symptomatic osteoporosis in a man with hyperprolactinemic hypogonadism. Ann Intern Med 1986, 105: 543–5.
Prelevic G. Osteoporosis in men. J R Soc Med 2001, 94: 620–3.
Cummings S, Black D, Nevitt M, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993, 341: 72–5.
Bonnick SL. Densitometric anatomy. In: Bonnick SL eds. Bone densitometry in clinical practice. Totowa, New Jersey: Humana Press Inc. 1998, 31–64.
Schlechte J, El-Khoury G, Kathol M, Walkner L. Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1987, 64: 1021–6.
Benito M, Gomberg B, Wehrli F, et al. Deterioration of trabecular architecture in hypogonadal men. J Clin Endocrinol Metab 2003, 88: 1497–502.
Seeman E, Melton III L, O’Fallon W, Riggs B. Risk factors for spinal osteoporosis in men. Am J Med 1983, 75: 977–83.
Vestergaard P, Jorgensen J, Hagen C, et al. Fractures risk is increased in patients with deficiency or untreated prolactinomas — a case-control study. Clin Endocrinol (Oxf) 2002, 56: 159–67.
Colao A, Di Somma C, Piovonello R, et al. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab 1999, 84: 1919–24.
Byers R, Hoyland J, Braidman I. Osteoporosis in men: a cellular endocrine perspective of an increasingly common clinical problem. J Endocrinol 2001, 168: 353–62.
Holmes S, Economou G, Whitehouse R, Adams J, Shalet S. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994, 78: 669–74.
Ciccarelli E, Savino L, Carlevatto V, Bertagna A, Isaia G, Camanni F. Vertebral bone density in non-amenorrheic hyperprolactinaemic women. Clin Endocrinol (Oxf) 1988, 28: 1–6.
Klibanski A, Biller B, Rosenthal D, Schoenfeld D, Saxe V. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 1988, 67: 124–30.
Nystrom E, Leman J, Lundberg P, et al. Bone mineral content in normally menstruating women with hyperprolactinaemia. Horm Res 1988, 29: 214–7.
Finkelstein J, Klibanski A, Neer R. A longitudinal evaluation of bone mineral density in adult men histories of delayed puberty. J Clin Endocrinol Metab 1996, 81: 1152–5.
Guo C, Jones T, Eastell R. Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density & bone turnover. J Clin Endocrinol Metab 1997, 82: 658–65.
Mittan D, Lee S, Miller E, Perez R, Basler J, Bruder J. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002, 87: 3656–61.
Carter J, Tyson J, Tolis G, Van Vliet S, Faiman C, Friesen H. Prolactin- secreting tumors and hypogonadism in 22 men. N Engl J Med 1978, 299: 847–52.
Pinzone J, Katznelson L, Danila D, Pauler D, Miller C, Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 2000, 85: 3053–7.
Kayath M, Lengyel A, Vieira J. Prevalence and magnitude of osteopenia in patients with prolactinoma. Braz J Med Biol Res 1993, 26: 933–41.
Klibanski A, Neer R, Beitins I, Ridgway C, Zervas N, McArthur J. Decreased bone density in hyperprolactinemic women. N Engl J Med 1980, 303: 1511–4.
Braidman I, Baris C, Wood L, et al. Preliminary evidence for impaired estrogen receptor-alpha protein expression in osteoblasts and osteocytes from men with idiopathic osteoporosis. Bone 2000, 26: 423–7.
Morishima A, Grumbach M, Simpson E, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995, 80: 3689–98.
Ohgphipadhanakul B, Rajatanavin R, Chanprasertyothin S, Oiaseu N, Chailurkit L. Serum oestradiol and oestrogenreceptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males. Clin Endocrinol (Oxf) 1998, 49: 803–9.
Center JR, Nguyen TV, Sambrook PN, Eisman JA. Hormonal and biochemical parameters in the determination of osteoporosis in elderly men. J Clin Endocrinol Metab 1999, 84: 3626–35.
Carlsen CG, Soerensen TH, Eriksen EF. Prevalence of low serum estradiol levels in male osteoporosis. Osteoporos Int 2000, 11: 697–701.
Khosla S, Melton III L, Atkinson E, O’Fallon W. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001, 86: 3555–61.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Naliato, E.C.O., Farias, M.L.F., Braucks, G.R. et al. Prevalence of osteopenia in men with prolactinoma. J Endocrinol Invest 28, 12–17 (2005). https://doi.org/10.1007/BF03345523
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345523